10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2011

OR

[    ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934

From the transition period from ___________ to ____________.

Commission File Number 000-51750

PHOENIX  MEDICAL SOFTWARE, INC.

(Exact name of small business issuer as specified in its charter)

Nevada	20-4846807
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

604 Creekview, Ovilla, Texas 75154

(Address of principal executive offices)

  (800) 843-8179

(Issuer's telephone number)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:.  Yes [ X ]   No [     ].

Indicate by a check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” ”accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [   ]	Accelerated Filer [  ]
Non-Accelerated Filer   [   ]	Smaller Reporting Company [X]

Indicate by a check mark whether the company is a shell company (as defined by Rule 12b-2 of the Exchange Act:  Yes [   ]   No [X].

As of May 16, 2010 there were 9,513,667 shares of Common Stock of the issuer outstanding.

TABLE OF CONTENTS

	PART I FINANCIAL STATEMENTS
Item 1	Financial Statements	3
Item 2	Management's Discussion and Analysis or Plan of Operation	7
	PART II OTHER INFORMATION
Item 1	Legal Proceedings	11
Item 2	Changes in Securities	11
Item 3	Default upon Senior Securities	11
Item 4	Submission of Matters to a Vote of Security Holders	11
Item 5	Other Information	11

2

PHOENIX MEDICAL SOFTWARE, INC. (FORMERLY TRIPLE A MEDICAL, INC.)
CONSOLIDATED BALANCE SHEETS
(Unaudited)
	March 31, 2011			December 31, 2010
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	23,164		$	222,348
Accounts receivable, net of allowance for doubtful accounts of $290,685       and $216,825		69,493			107,439
Total Current Assets		92,657			329,787
Developed software, net		113,878			133,007
TOTAL ASSETS	$	206,535		$	462,794
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	174,481		$	153,483
Line of credit		33,282			34,691
Advanced from shareholder		5,200			5,200
Total Current Liabilities		212,963			193,374
STOCKHOLDERS' EQUITY
Preferred stock, $0.01 par value, 20,000,000 authorized,
none issued and outstanding		-			-
Common stock, $0.01 par value, 50,000,000 authorized,
9,513,667 and 9,513,667 issued and outstanding, respectively		9,514			9,514
Additional paid-in-capital		2,016,234			2,016,234
Subscription deposits		2,625			2,625
Accumulated deficit		(2,034,801	)		(1,758,953	)
Total stockholders’ equity		(6,428	)		269,420
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	206,535		$	462,794
See accompanying summary of accounting policies and notes to unaudited consolidated financial statements.

3

PHOENIX MEDICAL SOFTWARE, INC.

(FORMERLY TRIPLE A MEDICAL, INC.)

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months Ended March 31, 2011 and 2010

(Unaudited

		Three Months Ended March 31,
REVENUE	$	382,432		$	357,799
OPERATING EXPENSES:
Depreciation and amortization		19,129			21,183
Selling, general and administrative		639,168			450,007
Total operating expenses		658,297			471,190
Loss from operations		(275,865	)		(113,391	)
OTHER INCOME
Interest income		17			45
Net loss	$	(275,848	)	$	(113,346	)
Basic and diluted weighted average shares outstanding		9,513,667			9,493,148
Basic and diluted net loss per share	$	(0.03	)	$	(0.01	)

 See accompanying summary of accounting policies and notes to unaudited consolidated financial statements.

4

PHOENIX MEDICAL SOFTWARE, INC.

(FORMERLY TRIPLE A MEDICAL, INC.)

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Three months Ended March 31, 2011 and 2010

(Unaudited)

	Three months Ended
	March 31,
	2011			2010
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(275,848	)	$	(113,346	)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization		19,129			21,183
Stock issued for services		-			85,000
Bad debt expense		73,860			11,508
Change in operating assets and liabilities:
Accounts receivable		(35,914)			(61,078	)
Accounts payable and accrued expenses		20,998			15,679
NET CASH USED IN OPERATING ACTIVITIES		(197,775	)		(41,054	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of stock, including stock subscription deposits		-			17,625
Payments on line of credit		(1,409)			(1,307	)
Payments to shareholder		-			(22,910)
NET CASH USED IN FINANCING ACTIVITIES		(1,409	)		(6,592	)
NET DECREASE IN CASH		(199,184	)		(47,646	)
CASH, BEGINNING OF PERIOD		222,348			132,993
CASH, END OF PERIOD	$	23,164		$	85,347
NON-CASH TRANSACTIONS
Common stock issued for conversion of debt	$	-		$	15,000
SUPPLEMENTAL DISCLOSURES
Interest paid	$	-		$	-
Income taxes paid		-			-

 See accompanying summary of accounting policies and notes to unaudited consolidated financial statements.

5

PHOENIX MEDICAL SOFTWARE, INC.

(FORMERLY TRIPLE A MEDICAL, INC.)

Notes to the Consolidated Financial Statements

(Unaudited)

NOTE 1--BASIS OF PRESENTATION

The accompanying unaudited interim consolidated financial statements of Phoenix Medical Software, Inc. (formerly Triple A Medical, Inc.) (“Phoenix Medical”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the rules and regulations of the Securities and Exchange Commission.  They do not include all information and notes required by U.S. generally accepted accounting principles for complete financial statements.  These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes contained in Phoenix Medical’s Annual Report on Form 10-K filed on March 31, 2011 for the year ended December 31, 2010.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented have been included.  The results of operations for interim periods are not necessarily indicative of the results that may be expected for any other interim period or for the full year.

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Certain 2010 amounts have been reclassed to agree with the 2011 classifications.

NOTE 2--GOING CONCERN

Phoenix Medical has recurring losses and an accumulated deficit.  Additionally, Phoenix Medical has incurred recurring deficits in cash flows from operating activities. These factors raise substantial doubt about the Company’s ability to continue as a going concern. However, Phoenix Medical's financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

Phoenix Medical's ability to continue as a going concern is dependent upon its ability to successfully market and implement its developed software product and to achieve profitable operations.  The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties.

 NOTE 3--RELATED PARTY TRANSACTIONS

In order to fund the development of the software, Phoenix Medical entered into an ‘Investment and Net Revenue Agreement’ with Phoenix Ortho, LLC (ORTHO), an entity controlled by a relative of the President of Phoenix Medical. In exchange for this contributed capital, Phoenix Medical provided ORTHO with an income participation interest in its operations.  The terms of this agreement require Phoenix Medical to pay ORTHO 33.1% of the net revenues generated by the business in the immediately preceding month.

As of December 31, 2010 and March 31, 2011, Phoenix Medical had unpaid advances owed to Paul McCune, the sole Director of the Company. The unpaid advance totaling to  $5,200 as of March 31, 2011 and December 31, 2010 is unsecured, bears no interest and is due on demand.

The Company rents office space from the President at $5,000 per month.  The expense for the three months ended March 31, 2011 and 2010 was $15,000.

6

 ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS

This report contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  The Company’s actual results could differ materially from those set forth on the forward looking statements as a result of the risks set forth in the Company’s filings with the Securities and Exchange Commission, general economic conditions, and changes in the assumptions used in making such forward looking statements.

General

The Company was founded to create electronic healthcare software applications.  The initial development is an Electronic Health Record (EHR), specifically designed to meet the needs of orthopedic physicians. For the past four years, our President, Morgan McCune, has worked directly with dozens of orthopedic physicians in more than 40 states.  He has reviewed orthopedic clinical research and extensively surveyed reference materials.  Based upon the research, Mr. McCune created a database with a graphical interface to assist orthopedic physicians with the documentation of the patient encounter.

The three months ended March 31, 2011 saw the Company to continue to drive revenue through both system contracts and legacy maintenance revenue.

RESULTS FOR THE FISCAL QUARTER ENDED MARCH 31, 2011

During the three months ended March 31, 2011, we continued marketing our software and following up on sales leads and experienced moderate growth over the first three months of 2010. The sales cycle can be anywhere from three months to one year.  In addition to a couple independent sales persons and alliances with marketing partners, we have a full time salesman on commission only.  Our sales leads continue to be generated and followed up on as we receive them from our own efforts by attendance at trade shows and from referrals from our industry cross marketing agreements. We have hit a stage in our business where we have our software developed and running smoothly and our infrastructure built so that we can install and maintain a multiple number of installations. During of the year ending December 31, 2010 we ran into a cash squeeze whereby the cost to maintain our infrastructure, which we estimate we need sales of approximately $500,000 per quarter, was considerably more than our sales. The first quarter of 2010, although better than the first quarter of 2009, fell short of the cash-flow neutral sales target; our second quarter of 2010, our best quarter ever at $596,388, generated a small operating profit of $4,680: our third quarter of 2010, generated $468,017.  We feel we are well positioned to for the fourth quarter of 2010 and for 2011. 

REVENUE. Revenue in the three months ended March 31, 2011 was $382,432 compared to $357,799 in the three months ended March 31, 2010.

The fluctuation in sales is due to the timing of closing sales contracts.  Please reference the table below to view the Installation Contracts quarter-to-date (QTD) for 201 versus 2010.

	2011		2010
		Contracts		Contracts
Installation Contracts	$181,945	3	$307,033	5
Maintenance/Other	200,487	25	50,766	12
TOTAL	$382,432		$357,799

7

Revenue for the three month period ended March 31, 2011 was impacted by two new implementation contracts and a carryover from 2010 with the difference related to maintenance/service on existing installations.  During the three ended March 31, 2011 there were a total of 25 customers making up the service/maintenance revenue of $200,847.  Monthly service agreements can vary from $500 to over $5,000 depending on the installation and support contracted.  In contrast, during the three and nine month periods ended March 31, 2010 there were a total of 12 customers making up the service revenue of $50,766.  Monthly maintenance revenue is important to establishing consistent cash flow and profitability once the Company reaches the right level of critical mass.

Installation contract revenue for the three months ended March 31, 2011 was $181,945 compared to $307,033 for the three months ended March 31, 2010.  In 2011 there have been 3 new/carryover installation contracts with average billing of $60,600.  In 2010 there were five new installation contracts with average billing of $61,400.

EXPENSES. Total operating expenses, not including depreciation expense, were $639,168 for the three months March 31, 2011 compared to $450,007 for the three months ended March 31, 2010.  

The increase in expenses of about $189,000 in the three month period ended March 31, 2011 is due to four main factors. Increased employee leasing of $137,000 (staffed-up in fiscal fourth quarter of 2010 and maintained staff level in fiscal first quarter of 2011), increased travel and trade shows of $71,000 (continuing to solicit customers), bad debt expense of $55,000 and partially offset by decreased commissions of $93,000 (less executed installment contracts in 2011).

Depreciation and amortization expense was $19,129 for the three months ended March 31, 2011 and $21,181 for the three months ended March 31, 2010.  

OTHER INCOME. We had interest income of $17 and $45 for the three months ended March 31, 2011 and 2010, respectively.

NET LOSS. Net loss for the three months ended March 31, 2011 was $275,848 compared to net loss of $113,346 for the three months ended March 31, 2010.  

Net loss for the three month period ended March 31, 2011 increased by $162,502 compared to the three month period ended March 31, 2010.  The increase is directly related to the net impact of revenue and expenses as discussed above.

LIQUIDITY AND CAPITAL RESOURCES. Our cash balance at March 31, 2011 was $23,164 compared to $222,348 at December 31, 2010.  As discussed in Note 2 the Company has recurring losses and an accumulated deficit.  Additionally, Phoenix Medical has incurred recurring deficits in cash flows from operating activities. These factors raise substantial doubt about the Company’s ability to continue as a going concern.  The Company plans for liquidity needs on a short term and long term basis as follows:

Short Term Liquidity:

The company currently relies on short-term financing of working capital from individual investors and also shareholder advances, when necessary, to fund operations.

Long Term Liquidity:

The long term liquidity needs of the Company are projected to be met primarily through the cash flow provided by operations.  Although our operating cash flow from operations is negative $197,775 for the three months ended March 31, 2011, we expect fiscal 2011 to be similar to 2010 whereby we will be begin implementing contracts in the fiscal second quarter. As we sign new contracts and perpetuate maintenance revenue we expect cash flow from operations to fund itself.

8

Capital Resources

Over the past few years we have noticed that our business does not have a seasonal trend.  Currently our revenue stream is geared toward installation contracts and as we grow we expect to see a more balanced revenue line between installation and maintenance sales.

We do not expect any significant change to our equity or debt structure and do not anticipate entering into any off-balance sheet arrangements.

Material Changes in Financial Condition

WORKING CAPITAL: Working capital declined by $256,718 to negative $120,305 since December 31, 2010.  This reduction is due to four main items.

Firstly: Cash decreased $199,184 due to maintaining expense structure on lower sales (unfavorable)

Secondly: Net accounts receivable decreased $37,946 (unfavorable)

Thirdly: AP/Accrued Expenses: $20,998 (unfavorable)

Employees

As of March 31, 2011, the Company had seven employees which it pays through an employee leasing agreement.  Four of the employees are support and/or technical personnel.

ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4: CONTROLS AND PROCEDURES

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2011.  This evaluation was accomplished under the supervision and with the participation of our chief executive officer / principal executive officer, and chief financial officer / principal financial officer who concluded that our disclosure controls and procedures are not effective to ensure that all material information required to be filed in the quarterly Form 10-Q has been made known to them.

For purposes of this section, the term disclosure controls and procedures means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Act (15 U.S.C. 78a et seg.) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.  Disclosure, controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by in our reports filed under the Securities Exchange Act of 1934, as amended (the "Act") is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

9

Based upon an evaluation conducted for the period ended March 31, 2010, our Chief Executive and Chief Financial Officer as of March 31, 2010 and as of the date of this Report, has concluded that as of the end of the periods covered by this report, we have identified the following material weakness of our internal controls:

●  Reliance upon independent financial reporting consultants for review of critical accounting areas and disclosures and material non-standard transaction.

●  Lack of sufficient accounting staff which results in a lack of segregation of duties necessary for a good system of internal control.

In order to remedy our existing internal control deficiencies, as our finances allow, we will hire additional accounting staff.

Changes in Internal Controls over Financial Reporting

We have not yet made any changes in our internal controls over financial reporting that occurred during the period covered by this report on Form 10-Q/A that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

10

PART II

Items No. 1, 2, 3, 4, 5 - Not Applicable.

Item No. 6 - Exhibits and Reports on Form 8-K

(a) No reports on Form 8-K were filed during the three months ended March 31, 2011.

(b)   Exhibits

Exhibit Number		Name of Exhibit
31.1	Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 United States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

PHOENIX MEDICAL SOFTWARE, INC.

By /s/ P. Morgan McCune

P. Morgan McCune, President, CFO

Date: May 16, 2010

11

EX-31.1

EXHIBIT 31.1

CHIEF EXECUTIVE OFFICER CERTIFICATION

I, P. Morgan McCune, certify that:

1. I have reviewed this quarterly report on Form 10-Q of PHOENIX MEDICAL SOFTWARE, INC.

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this amended quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure  controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the  period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures  and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change to the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an quarterly report) that has materially affected, or is reasonably  likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 16, 20111

/s/ P. Morgan McCune

P. Morgan McCune

President and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CHIEF FINANCIAL OFFICER CERTIFICATION

I, P. Morgan McCune, certify that:

1. I have reviewed this quarterly report on Form 10-Q of PHOENIX MEDICALSOFTWARE, INC.

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this amended quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure  controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the  period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures  and presented in this report our conclusion about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change to the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an quarterly report) that has materially affected, or is reasonably  likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

  Date: May 16, 2011

/s/ P. Morgan McCune

P. Morgan McCune

President and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of PHOENIX MEDICAL SOFTWARE, INC. (the “Company”) on Form 10-Q for the period ended March 31, 2011 as filed with the Securities and Exchange Commission (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Dated:  May 16, 2011

/s/ P. Morgan McCune

Name: P. Morgan McCune

Title:  Chief Executive Officer

Dated:  May 16, 2011

/s/ P. Morgan McCune

Name: P. Morgan McCune

Title:  Chief Financial Officer